News coverage about Kala Pharmctls (NASDAQ:KALA) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kala Pharmctls earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.1335341651067 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Several research analysts have recently commented on the company. Bank of America Corporation assumed coverage on Kala Pharmctls in a research report on Monday, August 14th. They set a “buy” rating and a $33.00 price target for the company. J P Morgan Chase & Co assumed coverage on Kala Pharmctls in a research report on Monday, August 14th. They set an “overweight” rating and a $35.00 price target for the company. Wells Fargo & Company assumed coverage on Kala Pharmctls in a research report on Monday, August 14th. They set an “outperform” rating and a $24.00 price target for the company. Oppenheimer Holdings, Inc. assumed coverage on Kala Pharmctls in a research report on Tuesday, August 15th. They set an “outperform” rating and a $46.00 price target for the company. Finally, Wedbush assumed coverage on Kala Pharmctls in a research report on Monday, August 14th. They set an “outperform” rating and a $46.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, Kala Pharmctls currently has a consensus rating of “Buy” and a consensus price target of $36.80.

Shares of Kala Pharmctls (KALA) opened at 25.27 on Friday. The stock has a 50 day moving average price of $22.48 and a 200 day moving average price of $20.80. The firm’s market capitalization is $612.22 million. Kala Pharmctls has a 52 week low of $16.38 and a 52 week high of $26.75.

In other Kala Pharmctls news, major shareholder Associates L.L.C. Cdk purchased 215,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was purchased at an average cost of $15.00 per share, with a total value of $3,225,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Orbimed Advisors Llc purchased 319,333 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average cost of $15.00 per share, with a total value of $4,789,995.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 1,282,666 shares of company stock valued at $19,239,990.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-kala-pharmctls-kala-stock-price/1565709.html.

About Kala Pharmctls

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Insider Buying and Selling by Quarter for Kala Pharmctls (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmctls Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmctls and related companies with Analyst Ratings Network's FREE daily email newsletter.